IL275423A - Methods and preparations for inducing an immune response against hepatitis virus HBV) B) - Google Patents

Methods and preparations for inducing an immune response against hepatitis virus HBV) B)

Info

Publication number
IL275423A
IL275423A IL275423A IL27542320A IL275423A IL 275423 A IL275423 A IL 275423A IL 275423 A IL275423 A IL 275423A IL 27542320 A IL27542320 A IL 27542320A IL 275423 A IL275423 A IL 275423A
Authority
IL
Israel
Prior art keywords
hbv
virus
inducing
compositions
methods
Prior art date
Application number
IL275423A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bavarian Nordic As
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Janssen Sciences Ireland Unlimited Co filed Critical Bavarian Nordic As
Publication of IL275423A publication Critical patent/IL275423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
IL275423A 2017-12-19 2020-06-16 Methods and preparations for inducing an immune response against hepatitis virus HBV) B) IL275423A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19
PCT/IB2018/060257 WO2019123250A1 (fr) 2017-12-19 2018-12-18 Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)

Publications (1)

Publication Number Publication Date
IL275423A true IL275423A (en) 2020-08-31

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
IL275423A IL275423A (en) 2017-12-19 2020-06-16 Methods and preparations for inducing an immune response against hepatitis virus HBV) B)

Country Status (12)

Country Link
EP (1) EP3727446A1 (fr)
JP (1) JP2021506300A (fr)
KR (1) KR20200100745A (fr)
CN (1) CN111741766A (fr)
AU (1) AU2018389786A1 (fr)
BR (1) BR112020012273A2 (fr)
CA (1) CA3086325A1 (fr)
IL (1) IL275423A (fr)
MA (1) MA51312A (fr)
MX (1) MX2020006471A (fr)
SG (1) SG11202005710YA (fr)
WO (1) WO2019123250A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
EP3986458A1 (fr) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (fr) 1904-11-07 1905-03-14 William Waid Paddock Filtre a pression
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998043702A2 (fr) 1997-04-03 1998-10-08 Iacob Mathiesen Methode pour introduire des medicaments et des acides nucleiques dans le muscle squelettique
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
EP2428250A1 (fr) 1998-07-13 2012-03-14 Genetronics, Inc. Thérapie génique ciblant la peau et les muscles par champ magnétique pulsé
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (fr) 2002-04-25 2003-12-18 Crucell Holland B.V. Moyens et procede de production de vecteurs d'adenovirus
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1456230A2 (fr) 2001-12-04 2004-09-15 Bavarian Nordic A/S Vaccin a sous-unite de ns1 de flavivirus
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
CA2478508C (fr) 2002-04-25 2013-07-02 Crucell Holland B.V. Vecteurs adenoviraux stables et techniques de propagation de ces vecteurs
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
KR101261642B1 (ko) 2004-03-08 2013-05-06 아이커 메디칼 시스템스 인코포레이티드 치료 제제의 전기 매개식 이송을 위한 개선된 장치
CN101248173A (zh) * 2005-04-08 2008-08-20 墨尔本保健公司 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
AU2007313203B2 (en) 2006-10-17 2012-08-16 Vgx Pharmaceuticals, Llc Electroporation devices and methods of using same for electroporation of cells in mammals
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
CA2741724C (fr) 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoteurs pour expression virale recombinante
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
CA2770075C (fr) * 2009-08-07 2021-08-24 Perrine Martin Composition pour le traitement d'une infection par le virus de l'hepatite b
KR101879892B1 (ko) 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
MX380483B (es) 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
DK3329016T3 (da) 2015-07-31 2022-01-10 Bavarian Nordic As Promotorer til forbedring af ekspression i poxvirus
EP3402888B1 (fr) * 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Moyens et méthodes pour le traitement du vhb
NZ747635A (en) 2016-03-28 2024-05-31 Ichor Medical Systems Inc Method and apparatus for delivery of therapeutic agents

Also Published As

Publication number Publication date
CN111741766A (zh) 2020-10-02
EP3727446A1 (fr) 2020-10-28
JP2021506300A (ja) 2021-02-22
KR20200100745A (ko) 2020-08-26
MX2020006471A (es) 2020-09-22
SG11202005710YA (en) 2020-07-29
CA3086325A1 (fr) 2019-06-27
MA51312A (fr) 2020-10-28
BR112020012273A2 (pt) 2020-11-24
WO2019123250A1 (fr) 2019-06-27
AU2018389786A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
IL274298A (en) Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv)
IL275427A (en) Hepatitis virus vaccines HBV) B) and their uses
SG11201703638XA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
SG11201803474UA (en) Vaccines against hepatitis b virus
GB201708444D0 (en) Compositions and methods for inducing an immune response
IL258326B (en) Antibodies that neutralize the hepatitis b virus in potency and their uses
SG11202106483WA (en) Antibodies that neutralize hepatitis b virus and uses thereof
SG11202005710YA (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
IL275429A (en) Methods and device for administering hepatitis virus HBV vaccines) B)
SG11201610443WA (en) Influenza virus vaccines and uses thereof
EP3463448A4 (fr) Compositions et procédés de génération d'une réponse immunitaire contre un virus de l'hépatite b
ZA201806325B (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
GB201807932D0 (en) Compositions and methods for inducing an immune response
IL290924A (en) Vaccines for hepatitis b virus
GB201702193D0 (en) Hepatitis E virus vaccine
EP3244922A4 (fr) Méthodes d'induction d'une réponse immunitaire au virus de l'hépatite c
HK40039588A (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
HK40039938A (en) Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines
PL3244921T3 (pl) Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV